Literature DB >> 29415979

Autopsy case report of intravascular large B-cell lymphoma with neoplastic PD-L1 expression.

Ayako Sakakibara1, Yuichiro Inagaki2, Eiki Imaoka3, Eri Ishikawa1, Satoko Shimada1, Kazuyuki Shimada4, Yuka Suzuki1, Shigeo Nakamura1, Akira Satou5, Kei Kohno1.   

Abstract

Intravascular large B-cell lymphoma (IVLBCL) is a rare and clinically distinctive entity characterized by the almost exclusive growth of large cells within the lumen of blood vessels in particular capillaries. Reports of this peculiar disease, do not commonly address the PD-L1 expression on IVLBCL tumor cells. Here, we describe a 51-year-old Japanese woman who presented with rapidly progressive cognitive decline and higher brain dysfunction. CT scan and MRI revealed multiple ischemic foci in the cerebral hemispheres, ground-glass opacity in the lungs, and splenomegaly. Random skin biopsy for IVLBCL diagnosis yielded negative results. The patient experienced a rapidly deteriorating clinical course with no treatment, and died from the disease after 3 months of hospitalization. Post-mortem examination revealed systemic intravascular plugging of lymphoma cells, without mass lesions in the central nervous system or in visceral organs such as the lungs, liver, pituitary gland, ovaries, and uterus. The tumor cells were positive for CD10, CD20, BCL2, BCL6, and MUM1, but not other lineage-specific markers. Notably, the tumor cells showed strong PD-L1 expression. Our case was diagnosed as IVLBCL with neoplastic PD-L1 expression. These findings suggest that PD-L1 is associated with immune evasion of IVLBCL and may play a role in the pathogenesis and peculiar biological behavior of this unique disease. Additionally, PD-L1 may represent a possible therapeutic target for immune check-point inhibitors.

Entities:  

Keywords:  intravascular large B-cell lymphoma; neoplastic PD-L1 expression

Mesh:

Substances:

Year:  2018        PMID: 29415979      PMCID: PMC6144198          DOI: 10.3960/jslrt.17037

Source DB:  PubMed          Journal:  J Clin Exp Hematop        ISSN: 1346-4280


  4 in total

1.  PD-L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B-cell lymphoma treated with rituximab-based multi-agent chemotherapy.

Authors:  Yuka Suzuki; Kei Kohno; Kosei Matsue; Ayako Sakakibara; Eri Ishikawa; Satoko Shimada; Kazuyuki Shimada; Seiyo Mabuchi; Taishi Takahara; Seiichi Kato; Shigeo Nakamura; Akira Satou
Journal:  Cancer Med       Date:  2020-05-05       Impact factor: 4.452

2.  Pituitary Gland and Neurological Involvement in a Case of Hemophagocytic Syndrome Revealing an Intravascular Large B-Cell Lymphoma.

Authors:  Sylvain Raoul Simeni Njonnou; Bruno Couturier; Yannick Gombeir; Sylvain Verbanck; France Devuyst; Georges El Hachem; Ivan Theate; Anne-Laure Trepant; Virginie De Wilde; Frédéric-Alain Vandergheynst
Journal:  Case Rep Hematol       Date:  2019-04-28

Review 3.  Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review.

Authors:  Ayako Sakakibara; Kei Kohno; Eri Ishikawa; Yuka Suzuki; Yuta Tsuyuki; Satoko Shimada; Kazuyuki Shimada; Akira Satou; Taishi Takahara; Akiko Ohashi; Emiko Takahashi; Seiichi Kato; Shigeo Nakamura; Naoko Asano
Journal:  J Clin Exp Hematop       Date:  2021-09-10

4.  Rapid deterioration of intravascular large B-cell lymphoma with mass formation in the trigeminal nerve and multiple organ infiltration: An autopsy case report.

Authors:  Yuka Tanaka; Shuji Momose; Natsuko Takayanagi; Takayuki Tabayashi; Michihide Tokuhira; Jun-Ichi Tamaru; Masahiro Kizaki
Journal:  J Clin Exp Hematop       Date:  2021-11-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.